The global lentiviral vector CDMO market is set to witness a growth rate of 8% in the next 5 years. Growing demand for gene and cell therapies; expanding pipeline of gene therapy products; ...

ViroCell Biologics ("ViroCell" or the "Company"), a specialist viral vector Contract Development and Manufacturing ...

ViroCell manufactured a GMP lentiviral vector for UCL to accelerate research into prevention of relapse in childhood blood cancer UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing ...

For a second time in less than a month, a new CDMO has uncloaked. This time, Meribel Pharma Solutions is gracing the stage after its financial backer snapped up a string of production facilities ...

Frank Mathias, CEO of OXB, commented: “2024 was a year of strong commercial progress for OXB as we executed our multi-vector, multi-site strategy as a pure-play CDMO. With revenue growth of 44% ...

CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing ...

PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – is acquiring an entire equity stake in ...